Annexon, Inc. cotiza a 3.96 USD y tiene una capitalización bursátil de $751M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; co…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.28 | $-0.23 | $-0.28 |
| Estimado | $-0.28 | $-0.24 | $-0.30 | $-0.32 |
| Sorpresa | — | -16.7% | +23.3% | +12.5% |
| Métrica | ANNX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -97.7% | -40.4% | -57.3% |
| ROA | -74.5% | -32.0% | -42.4% |
| Current Ratio | 5.68 | 2.84 | +2.84 |
| Debt / Equity | — | 0.28 | — |